Tadalafil Tablet, Film Coated
Product Images NDC 75834-248

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 75834-248). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nivagen Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tadalafil-10-mg-30s (Tadalafil 10 mg 30s)

This is a package of Tadalafil tablets, with each tablet containing 10mg of Tadalafil USP. The tablets are manufactured in Vapi, Gujarat, India by Umedica Laboratories. The package contains 30 tablets with a shelf life until September 2020. The container should be kept away from children, and the tablets should not be split. The dosage instructions should be followed as per the accompanying information.*

FDA Label Image

Tadalafil-2-5-mg-30s (Tadalafil 2 5 mg 30s)

These are Tadalafil tablets, USP with each tablet having 2.5 g of Tadalafl USP. The package is child-resistant, and the tablets are for once-daily use. The manufacturer is Umedica Laboratories Py, Ltd, and they are dispensed in a light container. It is advised not to split the tablets, and each entire dose should be taken. The tablets should be stored at 25°C, with excursions allowed between 15 to 30°C. The usual dosage is specified in the accompanying literature. The tablets are manufactured for Nivagen Pharmaceuticals Inc, and the package also contains a warning to keep out of reach of children.*

FDA Label Image

Tadalafil-20-mg-30s (Tadalafil 20 mg 30s)

This is a description for a medication called Tadalafil, which comes in tablet form. The tablets contain 20mg of Tadalafil USP and should not be split. The entire dose should be taken. The medication is manufactured by Umedica Laboratories Pt. Ltd. and distributed by Nivagen Pharmaceuticals, Inc. The tablets should be stored at temperatures between 15°C to 30°C. The usual dosage is provided in the accompanying literature.*

FDA Label Image

Tadalafil-5-mg-30s (Tadalafil 5 mg 30s)

This is a description of a medication package for Tadalafil tablets containing 30 tablets, each with 5mg of Tadalafil USP. The package is manufactured by Umedica Laboratories Pvt. Ltd. and distributed by Nivagen Pharmaceuticals, Inc. The tablets should not be split and only the recommended dose should be taken. The package includes a warning to keep out of reach of children and that it should be dispensed in a light container. The package also includes a warning to store it at 25°C (77°F) and to avoid temperature excursions. The usual dosage is included in accompanying literature. The package was printed in September 2020.*

FDA Label Image

Tadalafil-figure-1 (Tadalafil Figure 1)

This appears to be a chart or table showing the difference in blood pressure measurements (systolic and diastolic) between taking Tadalafil (a medication used to treat erectile dysfunction) and a placebo. The measurements are taken in both a standing and supine position, and are plotted against time (in hours). However, the format and content are difficult to interpret without further context or a more clear copy of the chart/table.*

FDA Label Image

Tadalafil-figure-2 (Tadalafil Figure 2)

This is a graph showing the standing and supine systolic blood pressure (measured in mmHg) in relation to time post-dose (in hours) for individuals taking Tadalafil 20mg and doxazosin 8mg vs individuals taking a placebo and doxazosin 8mg. The graph displays data for up to 24 hours post-dose.*

FDA Label Image

Tadalafil-figure-3 (Tadalafil Figure 3)

This text presents a table showing systolic blood pressure (in mmHg) at different times after the administration of 20mg tadalafil and 8mg qd doxazosin or placebo and 8mg qd doxazosin. The readings are taken at 08:00 and 20:00.*

FDA Label Image

Tadalafil-figure-4 (Tadalafil Figure 4)

This is a graph showing the plasma concentration of Tadalafil (in micrograms per liter) over time (in hours) after consumption of various doses (20 mg, 5 mg, and once-daily 5 mg for 5 consecutive days). The graph shows that the maximum plasma concentration is achieved about 2 hours after taking the medication and that higher doses result in higher plasma concentrations.*

FDA Label Image

Tadalafil-figure-5 (Tadalafil Figure 5)

The text is a graph title presenting the "Change from Baseline in IPSS Total Score" for "Tadalafil Tablets 5 mg" over a 12-week duration of treatment.*

FDA Label Image

Tadalafil-figure-6 (Tadalafil Figure 6)

FDA Label Image

Tadalafil-figure-7 (Tadalafil Figure 7)

This text appears to be a chart or a graph showing the LS Mean Change from Baseline at Weeks 4, 12, and 26 for different therapies, including TadalafilFinasteride and Placebo/Finasteride. The chart also shows the Least-Squares Treatment Difference with negative values ranging from -2.0 to -6.0 and corresponding p-values of <0.05 and <0.001.*

FDA Label Image

Tadalafil-figure-8 (Tadalafil Figure 8)

FDA Label Image

Tadalafil-structure (Tadalafil Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.